The Food and Drug Administration has authorized the sale of 10 flavors of Zyn, a smokeless nicotine pouch, marking the first time regulators have approved nicotine pouches for sale in the U.S. The decision has sparked controversy, with critics raising concerns about its potential appeal to young people and its long-term health effects.
The Food and Drug Administration has authorized the sale of 10 flavors of Zyn , a smokeless nicotine pouch, marking the first time regulators have approved nicotine pouches for sale in the U.S. The decision comes after more than a decade of FDA review of company data intended to demonstrate that Zyn can serve as a less harmful alternative to cigarettes and traditional tobacco products. Zyn , which is popular in Scandinavian countries, contains nicotine and flavoring but no tobacco.
While the FDA maintains that Zyn contains fewer harmful ingredients than cigarettes and other forms of tobacco, which are linked to cancer and other life-threatening diseases, the decision has sparked controversy. FDA officials acknowledge that company data shows a substantial portion of adults who previously smoked switched completely to Zyn, but critics argue that the pouches could become addictive for young people. Antismoking groups have expressed concern that Zyn, with its appealing flavors, could follow a similar trajectory to e-cigarettes, which initially saw a surge in popularity but faced backlash due to a rise in underage vaping. The FDA has defended its decision, pointing to government survey data showing that fewer than 2 percent of American high school and middle school students used nicotine pouches last year. Supporters of Zyn argue that it functions similarly to nicotine gum and lozenges, releasing low levels of nicotine absorbed into the gums, helping to reduce cravings. The debate surrounding Zyn has even spilled into political discourse, with Democrats and Republicans clashing over its potential impact on youth. Senator Charles Schumer called for an investigation into Zyn, citing its appeal to teenagers, while several House Republicans warned that the government was attempting to ban nicotine. Conservative commentators like Tucker Carlson have also embraced Zyn. Philip Morris, the company that markets Zyn in the U.S., insists it does not employ online influencers or endorsements to promote the product. Zyn competes with similar pouches from companies like Altria
NICOTINE POUCHES ZYN FDA TOBACCO YOUTH ADDICTION HEALTH REGULATION
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves Sale of Zyn Nicotine Pouches, Sparking DebateThe FDA has authorized the sale of 10 flavors of Zyn, a smokeless nicotine pouch, sparking debate about its potential health risks and appeal to young people.
Read more »
FDA OKs sales of Zyn nicotine pouches, citing health benefits for adult smokersFederal health officials are backing the health benefits of nicotine pouches.
Read more »
FDA officially authorizes Zyn nicotine pouches for sale following health reviewRob Wile is a Pulitzer Prize-winning journalist covering breaking business stories for NBCNews.com.
Read more »
FDA OKs sales of Zyn nicotine pouches, citing health benefits for adult smokersFederal health officials are backing the health benefits of nicotine pouches, ruling that Philip Morris International’s Zyn can help adult smokers cut back or quit cigarettes.
Read more »
FDA Approves Sale of Nicotine Pouches For First TimeThe FDA has authorized the sale of nicotine pouches, a decision that has been met with both support and concern. The agency states that these pouches are less harmful than traditional tobacco products, but there are worries about their potential appeal to teenagers.
Read more »
FDA Approves Celltrion's Steqeyma as a Biosimilar to StelaraThe U.S. Food and Drug Administration (FDA) has approved Steqeyma (ustekinumab-stba), a biosimilar to ustekinumab (Stelara), developed by Celltrion. Steqeyma is indicated for the treatment of adults with active Crohn’s disease or ulcerative colitis and for both children aged ≥ 6 years and adults with moderate to severe plaque psoriasis or active psoriatic arthritis. It will be available in two formulations: a subcutaneous injection and an intravenous infusion.
Read more »